Anzeige
Mehr »
Donnerstag, 05.06.2025 - Börsentäglich über 12.000 News
Kupfer wird knapp! Jetzt mischen sich Medien ein - und ein Explorer liefert die Story zur Fantasie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D6Y4 | ISIN: US38942Q2021 | Ticker-Symbol:
NASDAQ
04.06.25 | 19:32
1,700 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CALCIMEDICA INC Chart 1 Jahr
5-Tage-Chart
CALCIMEDICA INC 5-Tage-Chart

Aktuelle News zur CALCIMEDICA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14.05.CalciMedica GAAP EPS of -$0.36 misses by $0.061
CALCIMEDICA Aktie jetzt für 0€ handeln
14.05.CalciMedica, Inc. - 8-K, Current Report1
14.05.CalciMedica, Inc.: CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates66Enrollment ongoing in Phase 2 KOURAGE trial of Auxora in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025 Presentations at...
► Artikel lesen
01.04.H.C. Wainwright maintains $16 target on CalciMedica stock4
27.03.CalciMedica, Inc. - 10-K, Annual Report1
27.03.CalciMedica, Inc.: CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates406Enrollment ongoing in Phase 2 KOURAGE trial of Auxora in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025 Post-hoc analysis...
► Artikel lesen
27.03.CalciMedica, Inc. - 8-K, Current Report-
05.03.CalciMedica secures credit facility for up to $32.5M1
05.03.CalciMedica sichert sich Kreditfazilität in Höhe von 32,5 Millionen US-Dollar2
04.03.CalciMedica reports reduced mortality in AKI trial with Auxora1
04.03.CalciMedica, Inc. (CALC): Among Penny Stocks with Insider Buying in 20251
04.03.CalciMedica, Inc. - 8-K, Current Report-
14.01.CalciMedica beruft neuen Direktor1
14.01.CalciMedica appoints new director amid clinical trials2
14.01.CalciMedica, Inc. - 8-K, Current Report-
20.12.24CalciMedica, Inc. - 8-K, Current Report-
13.11.24CalciMedica, Inc.: CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates153Additional positive data, including a win ratio analysis, announced from CARPO Phase 2b trial of Auxora in acute pancreatitis (AP); Company expects to be in a position...
► Artikel lesen
12.08.24CalciMedica, Inc.: CalciMedica Reports Second Quarter 2024 Financial Results and Provides Clinical & Corporate Updates624Positive topline data announced from CARPO, Phase 2b trial of Auxora in acute pancreatitis (AP); additional data to be presented at a medical meeting later this year First patient enrolled in KOURAGE...
► Artikel lesen
09.07.24CalciMedica, Inc.: CalciMedica Announces First Patient Enrolled in Phase 2 KOURAGE Trial of Auxora in Severe Acute Kidney Injury (AKI)215Development of Auxora in AKI is supported by both clinical and pre-clinical evidence Topline data expected in 2025 LA JOLLA, Calif., July 9, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica"...
► Artikel lesen
27.06.24CalciMedica, Inc.: CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora in Acute Pancreatitis (AP)260Primary objective of the trial met with statistically significant dose response with up to 43.6% relative reduction (2.1 day improvement) in median time to solid food tolerance versus placebo in hyper-inflamed...
► Artikel lesen
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1